Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
PaperCitations, authors & open-access status
Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 212 citations, 2019 year and hybrid oa status.
212
Citations
2019
Year
hybrid
OA Status